By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Ethiopia’s domestic pharmaceutical market growth is expected to be driven by a rising middle income base and urbanization at a rate of 5.4% per year, which leads to greater access to healthcare as cities have better infrastructure and healthcare capacities.
Imports account for 65% to 75% of the Ethiopian pharmaceutical market and are primarily sourced from India (22%), Netherlands (20%) and Belgium (13%).
Some 60% of total pharma spend in Ethiopia is public and social sector related, making the Ethiopian Pharmaceutical Supply Agency (EPSA) the single most powerful buyer in the country.
Kilinto Park is Africa’s first dedicated industrial park covering 279 hectares, with 136 hectares of land dedicated to pharmaceutical manufacturing.
For pharmaceuticals, the share of the public market is even higher – ~75% of all medicines consumed in Ethiopia is procured through the public sector.
The public sector procures products largely based on price, favoring generics medicines • ~90% of branded products are sold through the private pharmaceutical market.
Manufacturers indicated that closed bid RDF procurements by PFSA and protection of the domestic market through import tariffs are the most important market access incentives .
Existing domestic manufacturers indicate that the 25% price premium offered by PFSA in international tenders is less important, as they are seldom competitive even with the price advantage.
Regulatory challenges and access to foreign exchange are among the most significant challenges to pharmaceutical manufacturing in Ethiopia, and incentives aimed at facilitating these processes are important.
The healthcare service in Ethiopia has always consisted of a mixture of public, private and nongovernmental healthcare sectors. However, currently the public healthcare system is organized into a three-tier health care delivery system which was introduced in 2010 (FMOH, 2010).
The pharmaceutical sector in Ethiopia is regulated by Food, Medicine and Healthcare Administration and Control proclamation No. 661/2009(FDRE, 2010).
Accordingly, the Ethiopian Food, Medicines and Healthcare Administration and Control Authority (EFMHACA) under the Ministry of Health (MOH) and its Regional Regulatory Counterparts are in charge of enforcement of the major regulatory functions 3 including marketing authorization, regulatory inspection, licensing of premises, marketing surveillance and control, pharmacovigilance, clinical trial oversight, etc.
Ethiopia is one of the first African countries to develop a national strategy for pharmaceutical manufacturing – Strategy: to grow exports in addition to substituting imports and improving access to medicines.
The National Medicines Policy was issued in 1993 with a number of policy implementation instruments developed subsequently.
Majority of Ethiopia’s pharmaceutical requirements are now imported; this is a significant need that local manufacture has not yet been able to meet.
Ethiopia is also struggling with the delivery of various medical products disguised as counterfeit goods, as well as the trafficking of subpar and fake pharmaceuticals. The majority of over-the-counter medications in the nation are found at clinics and hospitals.
Ethiopia is a landlocked nation in Eastern Africa that shares borders with South Sudan, Eritrea, Kenya, Somalia, and Sudan. Ethiopia’s terrain is made up of high plateaus, with the Great Rift Valley dividing the country’s major mountain range.
Ethiopia’s manufacturing sector is still developing, and the pharmaceutical sector is no exception. With the assistance of the state and an active local market, things are going quickly. The landscape of the pharmaceutical sector has undergone tremendous transformation.
The Ethiopia Pharmaceutical Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Aspen launches new antiretroviral drug in Ethiopia: Aspen, a leading pharmaceutical company in Africa and the Middle East, has launched a new antiretroviral drug in Ethiopia. The new drug is a generic version of a popular antiretroviral drug, and it is expected to be more affordable than the currently available brand-name drug.
Merck launches new diabetes treatment in Ethiopia: Merck, a leading global pharmaceutical company, has launched a new diabetes treatment in Ethiopia. s.The new treatment is a once-weekly injectable medication, and it is designed to be more convenient for patients to take than the currently available treatment
GSK launches new vaccine for shingles in Ethiopia: GSK, a leading global pharmaceutical company, has launched a new vaccine for shingles in Ethiopia. The vaccine is designed to protect adults from shingles, which is a painful and debilitating disease caused by the varicella-zoster virus.
Fresenius Kabi launches premixed injectable antibiotics in Ethiopia: Fresenius Kabi, a global leader in medical care, has launched a range of premixed injectable antibiotics in Ethiopia. The new products are designed to improve the safety and efficacy of antibiotic treatment in the country.
Pfizer launches new pneumococcal vaccine in Ethiopia: Pfizer, a leading global pharmaceutical company, has launched a new pneumococcal vaccine in Ethiopia. The vaccine is designed to protect children from pneumococcal disease, which is a leading cause of pneumonia, meningitis, and sepsis in children under the age of five.
